Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer

Publication: npj Breast Cancer 12, 68 (2026). https://doi.org/10.1038/s41523-026-00932-1Authors: Sonya Reid; Read More

2026-05-27T09:46:35-04:00March 26th, 2026|Evidence, FLEX, Neoadjuvant, Other, Racial Disparities|

FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer

Publication: SABCS 2025, Presentation ID: PS5-09-19 Authors: Gold et Read More

2025-12-15T13:32:31-05:00December 15th, 2025|Evidence, FLEX, FLEX TIPS, Other|

Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients With Obesity Enrolled in FLEX

Publication: SABCS 2025, Presentation ID: PS4-09-09 Authors: Mazo Canola Read More

2026-05-12T11:31:35-04:00December 15th, 2025|Evidence, FLEX, Other, Racial Disparities|

HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study

Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et Read More

2025-12-16T10:39:58-05:00December 15th, 2025|Adjuvant, Evidence, FLEX, FLEX, Neoadjuvant|

70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer

Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et Read More

2025-12-15T13:52:56-05:00December 15th, 2025|Adjuvant, Evidence, FLEX, FLEX, Neoadjuvant|

Improved 3-Year IDFS With Anthracycline-Based Therapy for Patients With 70-Gene Signature High 2, Luminal B, HR+HER2- Early-Stage Breast Cancer

Publication: SABCS 2025, Presentation ID: PS2-07-03 Authors: O’Shaugnessy et Read More

2025-12-15T13:50:35-05:00December 15th, 2025|Adjuvant, Evidence, FLEX|
Go to Top